Teva Pharmaceutical Industries Ltd. ADR-0.81% $21.06B ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Earlier this month, Pfizer filed a lawsuit (HP-2022-000016) in the Royal Courts of Justice in London, seeking to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on ...

As of October 31, 2024, GSK plc (ADR) had a $73.6 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc (ADR)’s ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...